Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...

Rafe Uddin So Starlink’s role in a number of European countries means that it’s seen as an easy target, given Musk’s proximity to Trump. There are also fears about a peace settlement between Russia ...

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based ...

Drugmaker Novo Nordisk A/S (NVO) on Monday entered into an exclusive license agreement worth up to $2 billion with ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

As part of the agreement with a United Lab unit announced on Monday, Novo will make an upfront payment of $200 million and up to $1.8 billion upon the completion of certain development and sales ...

German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market ...

We will probably not have any clarification on how the reciprocal tariffs will play out until April 2 — provided Trump isn’t ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...

Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension ...